Risk factors for adverse events in first-line Helicobacter pylori eradication therapy with vonoprazan, amoxicillin, and clarithromycin

被引：0

作者：

Kajihara, Yusaku ^{[1
]}

机构：

[1] Fuyoukai Murakami Hosp, Dept Gastroenterol, 3-3-14 Hamada, Aomori 0300843, Japan

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2023年 / 113卷

关键词：

Adverse event; Helicobacter pylori; Risk factor; Vonoprazan;

D O I：

10.1016/j.ejim.2023.03.029

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：117 / 118

页数：2

相关论文

共 4 条

[1] Gender differences in pharmacological response
Anderson, Gail D.
[J]. EPILEPSY IN WOMEN: THE SCIENTIFIC BASIS FOR CLINICAL MANAGEMENT, 2008, 83 : 1 - 10
[2] Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Kanda, Y.
[J]. BONE MARROW TRANSPLANTATION, 2013, 48 (03) : 452 - 458
[3] Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication
Kikuchi, Sota
Nobeyama, Yoshimasa
Saeki, Hidehisa
Asahina, Akihiko
[J]. JOURNAL OF DERMATOLOGY, 2020, 47 (03) : 277 - 282
[4] Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
Sugimoto, Mitsushige
Yamaoka, Yoshio
[J]. FRONTIERS IN PHARMACOLOGY, 2019, 9